Researchers at the University of Michigan have expanded the use of a gene sequencing method called ribosome profiling to understand protein production in cells. This method, also known as Ribo-seq, has the potential to advance cancer research by identifying new targets for immunotherapy and other treatment approaches.
Ribo-seq works by taking a high-resolution snapshot of protein production in cells. This can help researchers to identify previously unknown protein-coding regions and to understand the proteins that cancer cells are producing.
This information can then be used to develop new drugs that target these proteins and to identify patients who are most likely to benefit from immunotherapy.
